特朗普承认，中国帮了美国大忙，但中方的核心关切，他却绝口不提

Core Points - The article discusses the contradictory statements made by President Trump regarding China's role in the fentanyl crisis, highlighting his fluctuating stance that aligns with trade tariff policies [1][3] - It emphasizes that despite Trump's claims, evidence shows a significant reduction in fentanyl from China since 2019, coinciding with China's strict regulatory measures [3][5] - The article critiques the U.S. healthcare system's failure to address the root causes of the opioid crisis, attributing it to domestic pharmaceutical practices rather than foreign supply [5][7] Summary by Sections U.S.-China Relations and Fentanyl - Trump's comments on China’s efforts to combat fentanyl are inconsistent, reflecting a broader strategy tied to trade tariffs [1] - The signing of the fentanyl trafficking law coincided with Trump's reversion to blaming China for the majority of fentanyl supply [1][3] Impact of China's Regulatory Measures - China's 2019 regulations led to a notable decrease in fentanyl-related deaths in the U.S., with a 20%-25% reduction in overdose fatalities [3][5] - U.S. reports indicate that since 2019, there has been "almost no detection" of fentanyl from China, contradicting Trump's narrative [3][5] Domestic Issues in the U.S. - The article highlights systemic failures in the U.S. healthcare system, where 80% of the world's opioids are consumed by only 5% of the global population [5] - Trump's proposed solutions, such as executing drug traffickers in China, are criticized as superficial and failing to address domestic pharmaceutical lobbying and prescription practices [5][7] - The ongoing opioid crisis in the U.S. is framed as a public health issue that cannot be resolved through political posturing or foreign blame [7]